Treats insomnia. ANDA 202929, held by Macleods Pharms. Eszopiclone.
As of Nov 14, 2026, ANDA 202929 (Eszopiclone), held by Macleods Pharms, was first approved by FDA on Jan 30, 2015, with 5 approved supplements and 0 published complete response letters.
Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). Eszopiclone tablets are indicated for the treatment of insomnia. Eszopiclone tablets has been shown to decrease sleep latency and improve sleep maintenance
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2015 | Original application | Approved | None posted |
| Eszopiclone1MG · tablet;oral | Eszopiclone | Rx |
| Eszopiclone2MG · tablet;oral | Eszopiclone | Rx |
| Eszopiclone3MG · tablet;oral | Eszopiclone | Rx |
| Jun 7, 2023 | Supplement 26Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 30, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
